Form 8.3 - Pfizer Inc. ...
17 Novembro 2015 - 9:55AM
UK Regulatory
/**/
RNS Number : 9229F
Capital Group Companies Inc
17 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1.
KEY INFORMATION
|
Name
of person dealing (Note
1)
|
The Capital Group Companies,
Inc.
|
|
Company dealt in
|
Pfizer Inc.
|
|
Class of relevant security to which the dealings being
disclosed relate (Note
2)
|
US$0.05 common stock (ISIN:
US7170811035)
|
|
Date of dealing
|
16 November 2015
|
2.
INTERESTS AND SHORT POSITIONS
(a)
Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1) Relevant securities
|
140,155,258 (2.2706%)
|
|
|
(2) Derivatives (other
than
options)
|
|
|
|
(3) Options and agreements to
purchase/sell
|
|
|
|
Total
|
140,155,258* (2.2706%)
|
|
|
|
|
|
|
|
|
(b)
Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
|
Class of relevant
security:
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1) Relevant securities
|
|
|
|
(2) Derivatives (other
than
options)
|
|
|
|
(3) Options and agreements to
purchase/sell
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
2.
DEALINGS (Note 4)
(a)
Purchases and sales
|
Purchase/sale
|
Number of relevant
securities
|
Price per unit (Note
5)
|
|
Sale
|
1,530,000
|
33.005 - USD
|
|
Sale
|
760,000
|
33.330 - USD
|
|
Sale
|
728,910
|
33.103 - USD
|
|
Sale
|
7,000
|
33.085 - USD
|
|
Sale
|
3,000
|
33.350 - USD
|
|
Purchase
|
200
|
33.245 - USD
|
|
Purchase
|
1,035
|
33.060 - USD
|
|
Purchase
|
7,100
|
33.248 - USD
|
(b)
Derivatives transactions (other than options transactions)
|
Product name,
e.g. CFD
|
Nature of transaction
(Note 6)
|
Number of relevant
securities
(Note 7)
|
Price per unit
(Note 5)
|
|
|
|
|
|
(c)
Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product name,
e.g. call
option
|
Writing, selling, purchasing, varying etc.
|
Number of securities to which the option relates (Note 7)
|
Exercise price
|
Type, e.g. American, European etc.
|
Expiry date
|
Option money paid/received per unit
(Note 5)
|
|
|
|
|
|
|
|
|
(ii)
Exercising
|
Product name,
e.g. call
option
|
Number of securities
|
Exercise price per unit
(Note 5)
|
|
|
|
|
(d)
Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature of transaction
(Note 8)
|
Details
|
Price per unit
(if
applicable) (Note 5)
|
|
|
|
|
3.
OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing
and any other person relating to the voting rights of any relevant securities under any option
referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9)
NO
|
Date of disclosure
|
16 November 2015
|
|
Contact name
|
Christopher Aquino
|
|
Telephone number
|
+213.615.0469
|
|
If a connected EFM, name of offeree/offeror with which connected
|
n/a
|
|
If a connected EFM, state nature of connection (Note
10)
|
n/a
|
Y
*1,080 US$0.05
common stock due to a transfer out.
This information is provided by RNS
The company news service from the
London Stock Exchange
END
ISEEAAFXFFASFEF
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
